

(Rs. in Lakhs)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	10,760	9,713	9,437	29,638	28,690	37,557
2 Other Income	12	4	4	61	35	73
3 Total Income	10,772	9,717	9,441	29,699	28,725	37,630
4 Expenses						
(a) Cost of Materials Consumed	2,175	2,680	2,273	6,769	5,696	7,513
(b) Purchases of Stock-in-Trade	1,517	809	1,849	3,831	4,934	5,861
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	131	(392)	(932)	(753)	(906)	(598)
(d) Employee Benefits Expense	2,437	2,441	2,281	7,186	6,841	9,097
(e) Finance Costs	16	23	36	70	145	175
(f) Depreciation and Amortisation Expense	419	420	416	1,255	1,224	1,636
(g) Other Expenses	2,370	2,263	2,477	6,878	7,460	9,769
Total Expenses	9,065	8,244	8,400	25,236	25,394	33,453
5 Profit before exceptional items and tax	1,707	1,473	1,041	4,463	3,331	4,177
6 Exceptional Items Gain/(Loss) (See Note 3)	-	-	-	-	-	(532)
7 Profit before tax	1,707	1,473	1,041	4,463	3,331	3,645
8 Income tax expenses						
a. Current Tax	536	473	327	1,420	948	1,010
b. Deferred Tax	(116)	(115)	(77)	(265)	(220)	(266)
9 Profit for the period	1,287	1,115	791	3,308	2,603	2,901
10 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(6)	(6)	(10)	(18)	(30)	(24)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	1	2	5	8	7
Other Comprehensive Income Net of Tax	(4)	(5)	(8)	(13)	(22)	(17)
11 Total Comprehensive Income for the period	1,283	1,110	783	3,295	2,581	2,884
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
13 Other Equity						16,334
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
(a) Basic	7.78	6.74	4.78	20.00	15.74	17.54
(b) Diluted	7.78	6.74	4.78	20.00	15.74	17.54

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 25, 2021.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- Exceptional items for the year ended March 31, 2020 relates to write off of an intangible asset under development. The Company does not expect any future economic benefits to flow to the Company hence the cost incurred till date have been charged off during the quarter ended March 31, 2020.
- The Company has considered internal and external information while finalizing various estimates and recoverability of assets in relation to its financial statement captions upto the date of approval of the financial results by the Board of Directors. The impact of Covid19 may be different from what is estimated as at such date of approval of the financial results and the Company will continue to monitor any material changes to future economic conditions.

For RPG Life Sciences Limited

Yugal Sikri
Managing Director
Mumbai, January 25, 2021